Patents Examined by Ellen J Marcsisin
-
Patent number: 11971354Abstract: Methods and systems for time-domain and wavelength domain resolved multiplexed time-resolved fluorescence of a sample having at least one of a first fluorescent label bound to a first analyte and a second fluorescent label bound to a second analyte. The sample also includes a third fluorescent label bound to a third analyte and a fourth fluorescent label bound to a fourth analyte. The first and second fluorescent labels emit wavelengths having a first and second lifetime. The third fluorescent label comprises an upconverting phosphor (UCP) emitting at a wavelength having a third lifetime, and the fourth fluorescent label comprises an infrared dye emitting at wavelength having a fourth lifetime. The methods and systems measure as a function of time intensities of at least one of more of the first, second, third, and fourth fluorescent labels.Type: GrantFiled: December 17, 2019Date of Patent: April 30, 2024Assignee: Molecular Devices, LLCInventor: Michael Katzlinger
-
Patent number: 11953504Abstract: The present disclosure relates to an antibody specifically binding to bovine pregnancy-associated glycoprotein 1 (bPAG1) or an antigen-binding fragment thereof. The present disclosure further relates to a hybridoma cell producing the antibody; a composition including the antibody as an effective ingredient for diagnosis of bovine pregnancy; and a kit for diagnosis of bovine pregnancy. The present disclosure also relates to a method of diagnosing bovine pregnancy. Binding specifically to bPAG1, which is a pregnancy-associated plasma protein in bovines, the antibody allows a simple diagnosis of pregnancy in animals such as bovines of which the reproduction is important, so that the antibody may be usefully applied in the livestock industry by increasing reproduction efficiency.Type: GrantFiled: May 15, 2020Date of Patent: April 9, 2024Assignee: SLSBIO CO., LTD.Inventors: Bong Hui Kim, Young Ju Ha, Se Young Kim, Ji Na Kim
-
Patent number: 11940448Abstract: Early detection of lysosomal storage diseases (LSDs) including Mucopolysaccharidosis Type I (MPS I) and Pompe Disease can greatly improve patient outcome as each disease can be fatal once symptoms emerge. Screening for MPS I and Pompe Disease using biological samples including dried blood spots (DBS), buccal swab, peripheral blood mononuclear cells (PBMCs), or white blood cells (WBCs) is described. The disclosed methods and assays provide a robust way to screen newborns for LSDs. The disclosed methods and assays can also allow rapid prediction of whether a patient with LSD will develop an immune response to enzyme replacement therapy (ERT), thus improving treatment for patients with LSDs. The disclosed methods and assays can also further reduce the number of false positives caused by pseudo deficiency cases of LSD, such as MPS I and Pompe Disease.Type: GrantFiled: March 31, 2021Date of Patent: March 26, 2024Assignee: Seattle Children's HospitalInventors: Sihoun Hahn, Christopher Collins, Remwilyn Dayuha, Fan Yi
-
Patent number: 11933782Abstract: Detector systems are described, based on a primary binding compound and a secondary binding compound used in combination with a support to detect a target in a sample. The detection systems include a liquid medium hosting a first binding compound specific to a target, the first binding compound comprising a label; and a solid medium hosting a second binding compound specific to the target, the second binding compound being different from and non-competitive with respect to the first binding compound.Type: GrantFiled: August 15, 2017Date of Patent: March 19, 2024Assignee: LAWRENCE LIVERMORE NATIONAL SECURITY, LLCInventor: Jane P. Bearinger
-
Patent number: 11927595Abstract: Disclosed is the invention to conduct immuno-adsorption of free 25(OH) vitamin D from blood or blood components, notably serum or plasma, after which the absorbed material is measured. A fluoro-alkyl surfactant is used to enhance the solubility of Vitamin D and allow the measurement of free Vitamin D2. The invention thus employs a binding protein to absorb the free 25(OH) vitamin D. Thereafter the binding protein comprising the 25-OH vitamin D is subjected to a competitive binding assay with a labeled vitamin D compound, preferably radiolabeled, fluorescent labeled, luminescent labeled, biotin labeled, gold labeled or enzyme labeled. Alternatively the immunocaptured 25-OH vitamin D can be quantitated by mass spectrometry.Type: GrantFiled: January 15, 2021Date of Patent: March 12, 2024Assignee: FUTURE DIAGNOSTICS B.V.Inventors: Michaël Franciscus Wilhelmus Cornelis Martens, George Henry Parsons, Franciscus Maria Anna Rosmalen, Leon Maria Jacobus Wilhelmus Swinkels
-
Patent number: 11912783Abstract: An object of the present invention is to provide a monoclonal antibody capable of sufficiently inhibiting a non-specific reaction caused by a non-specific factor, a non-specific reaction inhibitor containing the monoclonal antibody, and the like. The present invention relates to a monoclonal antibody against dog IgM produced by a hybridoma with accession No. NITE BP-02556.Type: GrantFiled: February 21, 2019Date of Patent: February 27, 2024Assignee: Tanaka Kikinzoku Kogyo K.K.Inventors: Keita Suzuki, Hisahiko Iwamoto
-
Patent number: 11913960Abstract: Methods measuring properdin function and kits for conducting ELISA Assays using anti-properdin antibodies and uses thereof are described.Type: GrantFiled: May 10, 2019Date of Patent: February 27, 2024Assignee: The University of ToledoInventor: Viviana P. Ferreira
-
Patent number: 11899016Abstract: The present disclosure is directed to multiplex assays, kits and methods, including automated methods, for identifying PD-L1 positive immune cells, PD-L1 positive tumor cells, and PD-L1 negative immune cells within a tissue sample using two dyes selected from diaminobenzidine (DAB), 4-(dimethylamino) azobenzene-4?-sulfonamide (DABSYL), tetramethylrhodamine (DISCOVERY Purple), N,N?-biscarboxypentyl-5,5?-disulfonato-indo-dicarbocyanine (Cy5), and Rhodamine 110 (Rhodamine).Type: GrantFiled: May 21, 2018Date of Patent: February 13, 2024Assignee: Ventana Medical Systems, Inc.Inventor: Chandler Morgan Birch
-
Patent number: 11867696Abstract: The present disclosure provides high-performance immunoreagents for use in a variety of immunologic assays and other related techniques. The immunoreagents comprise a primary antibody and a bridging antigen, wherein the bridging antigen is recognized by a detectable secondary antibody with high affinity. Also provided are compositions comprising panels of immunoreagents specific for multiple different target antigens and compositions comprising pairs of primary immunoreagents and their complementary detectable secondary antibodies. The paired primary immunoreagents and secondary antibodies are useful in a variety of immunologic assays, particularly in highly multiplexed assays, where the structure of the bridging antigen is varied in tandem with variation in the detectable secondary antibody, such that a multiplicity of immunoreagents are provided that are capable of simultaneously detecting a multiplicity of target antigens in a single assay.Type: GrantFiled: February 6, 2016Date of Patent: January 9, 2024Assignee: CELL IDX, INC.Inventor: David A. Schwartz
-
Patent number: 11841366Abstract: The invention relates generally to immunoassays, and more particularly to monoclonal antibodies and immunoassays for the differential detection and quantitation of a wild-type crystal protein, such as a wild-type-Cry1Ab, from Bacillus thuringiensis and hybrid crystal proteins, which comprise all or a significant portion of the wild-type Cry protein in complex biological samples comprising both the wild-type Cry protein and one or more of the hybrid Cry proteins.Type: GrantFiled: March 17, 2020Date of Patent: December 12, 2023Assignee: Syngenta Participations AGInventors: Simone Cummings, Julie Smith, Magda Foege
-
Patent number: 11802147Abstract: Amatoxins (AMAs) are lethal toxins found in a variety of mushroom species. Detection methods are needed to determine the occurrence of AMAs in mushroom species, often suspected in mushroom poisonings. Provided herein are novel, sensitive monoclonal antibodies (mAbs) detection and purification techniques utilizing the mAbs that show selectivity for ?-amanitin (?-AMA), ?-amanitin (?-AMA) and ?-amanitin (?-AMA).Type: GrantFiled: June 19, 2020Date of Patent: October 31, 2023Assignee: The United States of America, as represented by The Secretary of AgricultureInventors: Candace R. Bever, Larry H. Stanker, Robert M. Hnasko, Luisa W. Cheng
-
Patent number: 11788965Abstract: The disclosure provides a system, compositions, and methods for detecting ovarian cancer cells by photoacoustic flow cytometry.Type: GrantFiled: February 21, 2020Date of Patent: October 17, 2023Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITYInventors: Barbara Smith, Joel Lusk
-
Patent number: 11774447Abstract: This invention provides a method for diagnosis of rheumatoid arthritis of a subject, a method for assisting diagnosis of rheumatoid arthritis, and a method for monitoring disease activity of rheumatoid arthritis and/or therapeutic effects of an agent for rheumatoid arthritis, comprising detecting citrullination of an arginine residue of the inter-?-trypsin inhibitor heavy chain (ITIH) 4 in a biological sample obtained from the subject. This invention also provides a citrullinated protein derived from the protein having the amino acid sequence as shown in SEQ ID NO: 1 or 5 by modification of arginine 438 into citrulline or a fragment thereof, an antibody binding to such citrullinated protein, and an agent for diagnosis of rheumatoid arthritis comprising such antibody.Type: GrantFiled: July 2, 2018Date of Patent: October 3, 2023Assignee: University of TsukubaInventors: Isao Matsumoto, Takayuki Sumida, Hoshimi Kawaguchi
-
Patent number: 11768202Abstract: Provided are methods for diagnosing a disease in a subject with a previous streptococcal infection by determining the presence or absence of one or more autoantibodies in a biological sample from the subject, wherein the one or more autoantibodies recognize an antigen from a protein selected from the group consisting of ELAVL2, ELAVL3, ELAVL4, Nova-1, Nova-2, Cdr1, Cdr2; and Cdr3. The presence of such autoantibodies is indicative of a positive diagosis for a post-streptococcal disease such as PANDAS, post-GABHS glomerulonephritis, rheumatic fever, autism and Syndenham's chorea.Type: GrantFiled: December 4, 2018Date of Patent: September 26, 2023Assignee: Quest Diagnostics Investments LLCInventors: Stanley J. Naides, Joanna Popov
-
Patent number: 11718682Abstract: The present invention relates to antibodies or antigen binding fragments thereof that binds to human “TIMP2. Further provided are methods for treating subjects, including human subjects, in need of treatment with the isolated TIMP2 antibodies or antigen-binding fragments thereof disclosed herein. Further provided are pharmaceutical or sterile compositions of anti-TIMP2 antibodies and antigen-binding fragments of the invention, the antibody or antigen-binding fragment thereof is admixed with a pharmaceutically acceptable carrier or excipient. Further provided are kits comprising one or more components that include an anti-TIMP2 antibody or antigen-binding fragment thereof of the invention or a pharmaceutical composition thereof.Type: GrantFiled: April 4, 2018Date of Patent: August 8, 2023Assignee: ASTUTE MEDICAL, INC.Inventors: Ravi A. Vijayendran, Srivatsa Venkatasubbarao
-
Patent number: 11703504Abstract: An electrochemiluminescence method of detecting an analyte in a liquid sample and a corresponding analysis system. An analyte in a liquid sample is detected by first providing a receptacle containing a fluid comprising protein coated magnetic microparticles to a stirring unit. Stirring of the fluid is necessary since the density of the microparticles is usually higher than the density of the buffer fluid. Thus the microparticles tend to deposit on the bottom of the receptacle leading to an aggregation of the microparticles because of weak interactions. To obtain representative measurements a homogeneous distribution of the microparticles in the buffer fluid is necessary to ensure a constant concentration of microparticles for each analysis cycle. It is further necessary to provide disaggregation of the microparticles, which is also realized by stirring the fluid. Stirring is conducted with a rotational frequency that is adapted to the amount of fluid to be stirred.Type: GrantFiled: September 5, 2019Date of Patent: July 18, 2023Assignees: ROCHE DIAGNOSTICS OPERATIONS, INC., HITACHI HIGH-TECH CORPORATIONInventors: Ralf Kraus, Oliver Larbolette, Friedrich Staebler, Yoshihiro Yamashita, Yukinori Sakashita, Shinya Matsuoka, Michihiro Saito, Taku Sakazume, Katsuaki Takahashi
-
Patent number: 11680948Abstract: Methods and assays for detecting natalizumab in a sample, natalizumab-peptide complexes in a sample, and point-of-care devices for detecting natalizumab in a sample are described herein.Type: GrantFiled: August 11, 2017Date of Patent: June 20, 2023Assignee: ABREOS BIOSCIENCES, INC.Inventors: Bradley T. Messmer, Dina Uzri, Jessie-Farah Fecteau
-
Patent number: 11635428Abstract: According to one embodiment, a molecule detecting device includes a capturing section, a releasing section, and a detecting section. The capturing section is configured to, by combining a target molecule and a solubilizing agent with each other and thereby creating a composite body, capture the target molecule in a carrier liquid. The releasing section is configured to make the composite body release the target molecule therefrom in the carrier liquid. The detecting section is configured to carry out detection of the target molecule in the carrier liquid.Type: GrantFiled: September 10, 2020Date of Patent: April 25, 2023Assignee: Kabushiki Kaisha ToshibaInventors: Hiroko Miki, Atsunobu Isobayashi, Yoshiaki Sugizaki
-
Patent number: 11604186Abstract: A Western Blot assay is performed by performing a probing process on a membrane containing target proteins, by contacting the membrane with a fluorescent resonant energy transfer (FRET) solution and allowing the probing process to proceed for a probing time period. The probing process results in a target protein becoming labeled with both a donor chromophore and an acceptor chromophore, which are effective as a donor-acceptor pair for FRET when so linked to the target protein. While performing the probing process, the labeled target proteins are measured by irradiating the membrane with an excitation light to excite the donor chromophores, wherein in each labeled target protein, the excited donor chromophore transfers energy to the acceptor chromophore by FRET and, in response, the labeled target protein emits an emission light. The intensity of the emission light is then measured. The light measured may be light emitted from the donor chromophore and/or light emitted from the acceptor chromophore.Type: GrantFiled: October 17, 2018Date of Patent: March 14, 2023Assignee: Molecular Devices (Austria) GmbHInventors: Michael Katzlinger, Kamil Önder
-
Patent number: 11493521Abstract: Exemplary embodiments of the present invention relate to rapidly and easily test initial liver disease and more particularly to a monoclonal antibody for ?1-acid glycoprotein, a diagnosis kit for tracking progressive chronic hepatitis and liver fibrosis in an initial phase of liver disease by measuring the concentration of asialo-?1-acid glycoprotein (AsAGP) as a hepatocyte injury marker in a sample using the antibody, and a use thereof. Further, embodiments of the present invention provide a kit for specifically determining the degree of progressive chronic hepatitis and hepatic fibrosis from a blood sample and an immunochromatography strip, comprising a HRP-RCA II (Ricinus communis agglutinin II) conjugate or a Gold-RCA II conjugate specifically binding to asialo ?-1 acid glycoprotein.Type: GrantFiled: January 18, 2020Date of Patent: November 8, 2022Inventors: WangJo Cha, Hyunhyo Suh, Mikyung Chung, Jae-hyun Cho, Mi Sook Jeong, Dahee Yoon, Myung Hun Lee, Sunghong Kim, Pil Sang Park